Japan-headquartered Fujifilm Corporation's Life Sciences Group companies, a portfolio of businesses offering products, services and comprehensive solutions that span all stages of therapeutic development from discovery through to commercialization, has announced new names and identities as part of a strategic positioning effort.
The Group Companies’ new names, collaborative strategic focus, and structural alignment reflects Fujifilm’s commitment to Life Sciences, offering fully integrated, end-to-end solutions across the drug development lifecycle—from research and discovery to clinical and commercial manufacturing.
Fujifilm Irvine Scientific becomes Fujifilm Biosciences, providing a full spectrum of life sciences solutions built from a 55-year history as a cell culture pioneer.
Fujifilm Diosynth Biotechnologies will be known as Fujifilm Biotechnologies, serving global partners seeking CDMO services from preclinical to commercialisation across a range of scales for biologics, advanced therapies and vaccines.
Over the past 15 years, Fujifilm has invested over $10 billion through expansions and acquisitions to build its end-to-end life sciences capabilities to create an accelerated path toward greater patient access for advanced care.
Alongside Fujifilm Biosciences and Fujifilm Biotechnologies, the Fujifilm Life Sciences Group companies also include Fujifilm Cellular Dynamics, a leading developer and manufacturer of human induced pluripotent stem cells, Fujifilm Wako Pure Chemical Corporation, and Fujifilm Toyama Chemical Co., Ltd.
